

# Disease Landscape & Forecast Overview

Quick Start Guide

February 2022



# What is Disease Landscape & Forecast?

Disease Landscape & Forecast is part of a suite of Clarivate DRG applications and provides market intelligence and detailed market insights for the Biopharma and Biotech industries supported by detailed primary and secondary research. Report highlights:


- ✓ 10-year, annualized forecasts of drug-level sales and patient shares of key therapies segmented by brands/generics. Updated monthly.
- ✓ Disease-specific top-to-bottom epidemiology background, including etiology and pathophysiology, key populations, current and future therapeutic landscape and the market trajectory
- ✓ Supported by primary research interviews of KOLs and providers across G7 countries as well as by secondary research by in-house experts

# Disease Landscape & Forecast Key Benefits and Uses

- ✓ Evaluate market potential for your pipeline assets and those of your competitors
- ✓ Gauge the commercial outlook and impact of key market events on currently marketed drugs and those in R&D
- ✓ Optimize your long-term disease and development strategy, including drug lifecycle management
- ✓ Understand a disease from top to bottom, including etiology and pathophysiology, key populations, current and future therapeutic landscape and market trajectory

# Clarivate DRG Platform Login

To login to the DRG Clarivate platform, click on - <https://authentication.decisionresourcesgroup.com/login/Solutions>



The screenshot shows the Clarivate DRG login interface. At the top left is the Clarivate | DRG logo. At the top right are links for 'About Us' and 'Contact Us'. The main heading is 'Welcome to Clarivate DRG' in purple, followed by the text 'Whether you are a new or existing user, enter your email address'. Below this is a link for support: 'Having problems? Email [DRG.support@clarivate.com](mailto:DRG.support@clarivate.com)'. At the bottom left is the copyright notice '© 2022 Clarivate.' and at the bottom right are links for 'Privacy policy' and 'Terms of use'.

On the right side, there is a login form. The label 'Work email address' is above a text input field. The input field contains the placeholder text 'Work email address' and an email icon. A large purple arrow points from the right towards the input field. Below the input field is a green button labeled 'Get started'. Another large purple arrow points from the right towards the 'Get started' button.

\*You may be asked for a password if your company is not integrated with the DRG platform

# Get started using Disease, Company & Drug Insights Platform

Clarivate™ | DRG

About Us Contact Us

Welcome [redacted] from Clarivate

Hover over any link to learn more about each product platform. Green check marks indicate partial or full content is available to you as part of your current subscription.

Have a question? **2** Please contact us

### Understand the Market

Disease, Company & Drug Insights

- ✓ Disease, Company & Drug Insights Platform
  - Disease Insights
  - Epidemiology
  - Biosimilars
  - Company and Drug Insights

**3**

### Medtech

- ✓ Medtech Insights Platform
  - Market Insights (Medtech 360)
  - Brand Tracking (Pricetrack & Marketrack)
  - US Medical Supply Distribution

### US Market Access Insights

- ✓ US Market Access Insights Platform
  - Health Plan Analysis
  - Market Overviews
    - Market Overview Interactive Database
  - National MCO Analyzer
  - Power Profiles

### Optimize Access

#### US Formulary Data & Analytics

By Fingertip Formulary

- ✓ Account Management Dashboard
- ✓ Fingertip Accounts
- ✓ Fingertip Alerts
- ✓ Fingertip Analytics
- ✓ Fingertip Home Page (Legacy Platforms)
- ✓ Fingertip Restrictions
- ✓ Fingertip Validation Tool
- ✗ Fingertip PolicyTrack

#### US Lives Data & Analytics

- ✓ Employer Vantage (2020 Data)
- ✓ Employer Vantage (2021 Data)
- ✓ Integrated Payer Platform
- ✓ Managed Market Surveyor Suite (Including Pharmacy Benefit Evaluator)

#### Global Market Access

### Engage Customers

#### Sales Enablement

- ✓ Fingertip Publisher

#### Commercial Targeting

- ✓ Healthbase
- ✓ Medtech Insights Platform
  - Commercial Targeting (Procedure Finder)
- ✗ Field Force Navigator (FFN)

#### Digital/Multichannel Stakeholder Engagement

- ✓ Digital Insights Platform
  - Multichannel Physician Engagement
  - Multichannel Patient Engagement
  - Multichannel Payer Engagement

1.  
Go to:  
<https://authentication.decisionresourcesgroup.com/login>

2.  
Upon login screen, use your work e- mail address and password to login. If you experience any issues, please contact [DRG.support@clarivate.com](mailto:DRG.support@clarivate.com)

3.  
Click on the “Disease, Company & Drug Insights” link.

# Disease, Company & Drug Insights Home Page

The screenshot shows the Clarivate DRG website. A tooltip titled "Disease Landscape & Forecast" is overlaid on the left side of the page. The tooltip contains the following information:

- Geographic Coverage:** U.S., EU5, Japan
- Forecast:** 10-year, annualized, drug-level sales and patient share
- Primary Research:** Country-specific KOL interviews supplemented with survey data
- Epidemiology:** Diagnosed prevalent and drug-treated cases by country
- Emerging Therapy Coverage:** Key Phase II, III and PR products and select preclinical and Phase I products

Below this information is a "Recently Viewed" section with a "Clear" link and a list of diseases: Psoriasis, Non-Small-Cell Lung Cancer, Neuropathic Pain, Breast Cancer, Obesity/Overweight, Rare Diseases and Orphan Dr..., Systemic Lupus Erythematosus, Axial Spondyloarthritis, Ulcerative Colitis, and Asthma. A green button labeled "Browse diseases and topics" is at the bottom of the tooltip.

The main page features a search bar with the text "you looking for today?" and a "Browse All" link. Below the search bar is a "Multichannel Engagement" section. The page also includes a sidebar with links to "Disease Landscape & Forecast", "Niche & Rare Disease Landscape & Forecast", "Biosimilars", "China In-Depth", "Company & Drug Insights", and "Cortellis Supply Chain Network". The "Patient Populations" section lists "Epidemiology" and "Epidemiology Data Slicer". The "Treatment Analysis" section lists "Current Treatment Physician Insights", "Unmet Need", and "Treatment Algorithms Claims Data Analysis".

1

1. Hover over "Disease Landscape & Forecast / Learn more" link to view product highlights as well as links to recently viewed reports. Select Browse diseases and topics to jump to Disease Landscape & Forecast landing page

# Disease Landscape & Forecast Filters Page

The screenshot shows the Clarivate Disease Landscape & Forecast Filters page. The interface includes a top navigation bar with the Clarivate logo, 'DRG', a dropdown menu for 'Biopharma', and a search bar labeled 'Search within Biopharma'. On the left, there is a 'FILTERS' section with a search input and a 'Clear all' link. Below this is a list of filter categories: Ownership, Product type, and Geography. A 'QUICK LINKS' section lists various medical categories like Autoimmune & Inflammation, Cardiovascular, etc. The main content area displays '55 diseases & topics tagged to: Disease Landscape & Forecast'. A 'Recently viewed' section shows 'Non-Small-Cell Lung Cancer'. A 'What's covered?' dropdown menu is open, showing a list of topics with green checkmarks indicating ownership and red padlocks indicating non-subscription. The page also features a 'Browse All' button and a help icon.

**1.** Ownership, Product type or Geography filters to narrow your search

**2.** Select recently viewed disease topic or select from directory

**3.** Type in partial word search to bring up possible matches

**4.** Select "What's covered?" to see what content is owned (green checks) vs not subscribed (red padlocks)

# Disease Landscape & Forecast Report

**Clarivate | DRG** Biopharma Search within Biopharma

Home / Diseases / **Non-Small-Cell Lung Cancer** Notifications Off

At a Glance Landscape & Forecast Epidemiology Current Treatment Unmet Need Access & Reimbursement Geographic Focus: China Meet The Team

**Table of contents** Expand all

Search within Content

Overview

**Disease Landscape & Forecast**

- Key Updates
- Key Findings
- Market Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Emerging Therapies
- Access and Reimbursement Overview
- Methodology
- Appendix

**Key Updates**

Last updated 17 January 2022

**Q1 2022**

- Clarivate updates its NSCLC market forecast to include news on clinical data, important regulatory announcements, and new agents that have entered the late-phase development pipeline for NSCLC. The market impact of these clinical, developmental, and regulatory events is further discussed in the "Current Treatment," "Emerging Therapies," and "Market Outlook" sections.
- Keytruda shows efficacy as adjuvant treatment for resectable stage IB-IIIa NSCLC, regardless of PD-L1 expression. The Phase III KEYNOTE-091/PEARLS trial is evaluating Keytruda as an adjuvant therapy for stage IB-IIIa NSCLC after complete resection. DFS in the overall population and in NSCLC with TPS.PD-L1 ≥ 50% are the dual primary endpoints of this European trial, for which Merck & Co. is collaborating with ETOPE and EORTC. In January 2022, Keytruda met one of its dual primary endpoints of DFS among resectable stage IB-IIIa NSCLC, regardless of PD-L1 expression. Interestingly, the primary endpoint of DFS in NSCLC patients whose tumors are PD-L1-high (TPS.PD-L1 ≥ 50%) was not met. The company announced that the results will be presented at an upcoming medical conference and will be submitted to regulatory authorities.
- The EC grants conditional marketing authorization to Amgen's Lumykras for the treatment of previously treated metastatic NSCLC with a KRAS p.G12C mutation. Lumykras is a selective small-molecule inhibitor of the KRAS G12C oncoprotein. This approval is based on data from the Phase II CodeBreak-100 trial. The KRAS p.G12C mutation occurs in approximately 11-13% of NSCLC adenocarcinoma patients and is believed to be the most common KRAS mutation (Dunnet-Kane V, 2021; Scheffler M, 2019). Lumykras is the first-in-class targeted therapy for the treatment of KRAS p.G12C-positive NSCLC in Europe.
- The FDA grants RTD status to AbbVie's anti-c-MET ADc telisotuzumab vedotin for previously treated EGFR wild-type metastatic nonsquamous NSCLC patients with high tumor MET expression whose disease has progressed on or after platinum-based chemotherapy. This designation was based on encouraging interim analysis safety and efficacy data from the Phase II LUMINOSITY trial. The company plans to initiate the pivotal Phase III TeliMET NSCLC-01 trial evaluating telisotuzumab vedotin versus docetaxel in previously treated EGFR wild-type metastatic nonsquamous NSCLC with high tumor MET protein expression.

**Downloads**

MAIN CONTENT

- Disease Landscape & Forecast Full Report
- NSCLC - Key Findings Attachment
- Market Forecast Assumptions Attachment
- Market Forecast Dashboard Attachment

ADDITIONAL FILES

- Disease Landscape & Forecast Table of Contents
- All Figures
- All Tables

**Meet the Team**

Arman Esfandiari

1.  
DL&F Table of contents

2.  
Reports can be downloaded by selecting the files of interest. The accompanying PowerPoint diagrams and Excel tables can be downloaded as separate documents.

3.  
Type in partial word search to bring up possible matches in the report (word matches highlighted in yellow in report)



# Market Forecast Dashboard & Assumptions

**Clarivate™ | DRG** Biopharma Search within Biopharma

Home / Diseases / **Non-Small-Cell Lung Cancer** Notifications Off

At a Glance **Landscape & Forecast** Epidemiology Current Treatment Unmet Need Access & Reimbursement Geographic Focus: China Meet The Team

**Table of contents** Expand all

Search within Content

Overview

**Disease Landscape & Forecast**

- Key Updates
- Key Findings
- Market Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Emerging Therapies
- Access and Reimbursement Overview
- Methodology
- Appendix

**Key Updates**

Last updated 17 January 2022

**Q1 2022**

- Clarivate updates its NSCLC market forecast to include news on clinical data, important regulatory announcements, and new agents that have entered the late-phase development pipeline for NSCLC.** The market impact of these clinical, developmental, and regulatory events is further discussed in the "Current Treatment," "Emerging Therapies," and "Market Outlook" sections.
- Keytruda shows efficacy as adjuvant treatment for resectable stage IB-IIIa NSCLC, regardless of PD-L1 expression.** The Phase III KEYNOTE-091/PEARLS trial is evaluating Keytruda as an adjuvant therapy for stage IB-IIIa NSCLC after complete resection. DFS in the overall population and in NSCLC with TPS.PD-L1 ≥ 50% are the dual primary endpoints of this European trial, for which Merck & Co. is collaborating with EORTC. In January 2022, Keytruda met one of its dual primary endpoints of DFS among resectable stage IB-IIIa NSCLC, regardless of PD-L1 expression. Interestingly, the primary endpoint of DFS in NSCLC patients whose tumors are PD-L1-high (TPS.PD-L1 ≥ 50%) was not met. The company announced that the results will be presented at an upcoming medical conference and will be submitted to regulatory authorities.
- The EC grants conditional marketing authorization to Amgen's Lumykras for the treatment of previously treated metastatic NSCLC with a KRAS p.G12C mutation.** Lumykras is a selective small-molecule inhibitor of the KRAS G12C oncoprotein. This approval is based on data from the Phase II CodeBreak-100 trial. The KRAS p.G12C mutation occurs in approximately 11-13% of NSCLC adenocarcinoma patients and is believed to be the most common KRAS mutation (Dunnet-Kane V, 2021; Scheffler M, 2019). Lumykras is the first-in-class targeted therapy for the treatment of KRAS p.G12C-positive NSCLC in Europe.
- The FDA grants RTD status to AbbVie's anti-c-MET ADc telisotuzumab vedotin for previously treated EGFR wild-type metastatic nonsquamous NSCLC patients with high tumor MET expression whose disease has progressed on or after platinum-based chemotherapy.** This designation was based on encouraging interim analysis safety and efficacy data from the Phase II LUMINOSITY trial. The company plans to initiate the pivotal Phase III TeliMET NSCLC-01 trial evaluating telisotuzumab vedotin versus docetaxel in previously treated EGFR wild-type metastatic nonsquamous NSCLC with high tumor MET protein expression.

**Downloads**

**MAIN CONTENT**

- Disease Landscape & Forecast Full Report
- NSCLC - Key Findings Attachment
- Market Forecast Assumptions Attachment**
- Market Forecast Dashboard Attachment**

**ADDITIONAL FILES**

- Disease Landscape & Forecast Table of Contents
- All Figures
- All Tables

**Meet the Team**

Arman Esfandjari

1. Click on "Market Forecast Assumptions" (MFA) and "Market Forecast Dashboard" to view forecast reports. MFA is a great resource for understanding all the assumptions that went into the forecast.

# Market Forecast Assumptions

**Clarivate™ | DRG**

Welcome to Clarivate's Market Forecast Assumptions file for NSCLC!  
This flat file provides a comprehensive view of Clarivate's 10-year, annualized, patient-based market forecast assumptions for NSCLC, including epidemiology, drug-treatable and drug-treated estimates, cycles, compliance, patient share, pricing, generic / biosimilar erosion, and resulting drug sales for all countries and populations included in this study. The data underlying this tool are identical to those found in the corresponding Market Forecast Dashboard Excel deliverable that accompanies this *Disease Landscape & Forecast* title.

**About Our Bottom-Up, Patient-Based Market Forecasts**  
Disease- and therapy-area-aligned analysts at Clarivate create each *Disease Landscape & Forecast* market model. We build our patient-based model upon our gold-standard epidemiology, which is provided by Clarivate's dedicated team of in-house epidemiologists. We update our bottom-up market forecasts as needed during a 12-month report cycle as important drug development and market events unfold.

**How to Navigate the Geography Tabs**  
Each country / region tab presents key data from our forecast.  
- Scroll horizontally to see the assumptions for all forecast variables that generate sales at the drug and class level.  
- Scroll vertically to see our forecast in each clinically and commercially relevant patient population / segment.  
- Use the grouping tool to expand or collapse for easier navigation and viewing.

**Forecast Data By Drug**

Sales (\$M)	Y0	Y1	Y2	Y3	Y4	Y5	Y6	Y7	Y8	Y9	Y10
<b>Total Indication</b>	1,675.4	1,623.2	1,663.9	1,729.8	1,860.8	2,058.4	2,189.0	2,258.6	2,290.3	2,319.6	2,347.7
<b>Drug Class 1</b>	480.6	484.0	501.7	548.9	665.9	846.4	958.8	1,011.1	1,026.7	1,040.1	1,053.7
Drug 1	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5
Brand	-	-	-	-	-	-	-	-	-	-	-
Generic	1.4	1.4	1.4	1.4	1.4	1.4	1.5	1.5	1.5	1.5	1.5
Drug 2	153.2	148.1	150.4	152.0	157.2	160.6	165.5	167.8	169.7	171.7	173.6
Brand	31.8	21.5	21.8	22.1	22.8	23.3	24.0	24.4	24.6	24.9	25.2
Generic	121.4	126.6	128.5	129.9	134.3	137.3	141.5	143.5	145.1	146.7	148.4
<b>Drug Class 2</b>	1,194.7	1,139.2	1,162.3	1,180.9	1,194.9	1,212.0	1,230.2	1,247.5	1,263.6	1,279.5	1,293.9
Drug 3	630.6	643.9	656.9	667.6	675.7	686.3	697.0	706.9	716.0	724.9	733.0
Brand	381.4	389.4	397.3	403.7	408.7	415.1	421.5	427.5	433.0	438.4	443.3
Generic	249.2	254.5	259.6	263.8	267.1	271.2	275.5	279.4	283.0	286.5	289.7
<b>Segment 1</b>	97.1	96.5	98.8	149.9	333.0	552.4	690.4	819.6	962.5	1,018.9	887.1

**Patient Share**

	Y0	Y1	Y2	Y3	Y4	Y5	Y6	Y7
<b>Total Indication</b>	110.3%	110.6%	110.9%	110.9%	110.7%	110.4%	110.4%	110.4%
<b>Drug Class 1</b>	39.9%	39.9%	39.8%	39.8%	39.8%	39.7%	39.7%	39.7%
Drug 1	5.6%	5.6%	5.6%	5.6%	5.5%	5.4%	5.4%	5.4%
Brand	-	-	-	-	-	-	-	-
Generic	5.6%	5.6%	5.6%	5.6%	5.5%	5.4%	5.4%	5.4%
Drug 2	34.3%	34.3%	34.3%	34.2%	34.3%	34.3%	34.3%	34.3%
Brand	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Generic	34.0%	34.1%	34.1%	34.0%	34.1%	34.0%	34.1%	34.1%
<b>Drug Class 2</b>	70.4%	70.8%	71.0%	71.1%	70.9%	70.7%	70.7%	70.7%
Drug 3	35.6%	35.7%	35.9%	35.9%	35.8%	35.8%	35.9%	35.9%
Brand	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%	1.8%
Generic	33.8%	33.9%	34.1%	34.1%	34.1%	34.0%	34.1%	34.1%
<b>Segment 1</b>	105.0%	107.0%	109.0%	107.0%	103.0%	103.0%	103.0%	103.0%

**Navigation Tabs:** Contact Us | Introduction | Recent Forecast Changes | Methodology and Approach | Key Events and Assumptions | United States | France | Germany | Italy | Spain | United Kingdom | Japan | Europe | Major Markets

**Annotations:**

- Use the grouping function to collapse / expand data
- Scroll horizontally to see all forecast variables at the drug and class level
- Scroll vertically to see forecasts for each DRUG

1. Market Forecast Assumptions consists of 5 informational tabs (Contact Us, Introduction, Recent Forecast Changes, Methodology and Approach, Key Events and Assumptions) and 9 report tabs (US, France, Germany, Italy, Spain, UK, Europe, Major Markets)

# Market Forecast Assumptions

1

1

2

3

4

Clarivate™

DRG

\*\* Scroll to our "Forecast by Regimen" section for Cycles, Compliance, and Price per Cycle data.

Forecast Data By Drug

Sales (\$M)

Total Non-Small-Cell Lung Cancer	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	12,507.49	15,020.42	16,845.22	18,688.17	20,822.96	22,999.83	24,950.51	26,350.39	27,099.09	27,131.94	26,803.76
Adeno stage IB and II	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	35.50	51.93	90.11	184.96	335.74	519.26	707.99	865.68	1,003.10	1,072.09	1,133.79
Adeno stage III	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	566.50	605.20	677.48	796.47	939.80	1,166.38	1,320.07	1,503.74	1,631.69	1,625.08	1,610.49
Adeno stage IV 1st line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	5,763.69	7,200.51	8,081.80	8,773.31	9,383.14	9,931.17	10,501.31	10,798.67	10,806.16	10,620.72	10,312.14
Adeno stage IV 2nd line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	1,108.26	1,205.49	1,279.04	1,424.89	1,707.40	1,974.31	2,159.01	2,355.88	2,484.33	2,589.08	2,641.09
Adeno stage IV 3rd line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	200.02	222.16	245.36	294.84	408.17	562.82	697.05	749.95	855.16	933.38	983.50
LC/O unverified histology stage IB and II	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	10.85	15.99	27.25	55.55	100.19	154.37	209.36	254.90	293.75	312.38	329.24
LC/O unverified histology stage III	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	194.84	207.08	230.67	269.66	316.50	391.01	440.52	499.80	539.38	535.83	529.68
LC/O unverified histology stage IV 1st line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	2,010.17	2,490.02	2,775.57	2,993.18	3,184.65	3,352.93	3,528.61	3,610.99	3,596.04	3,522.56	3,407.52
LC/O unverified histology stage IV 2nd line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	386.44	416.87	439.27	486.35	579.50	666.56	725.46	787.79	826.73	858.72	872.72
LC/O unverified histology stage IV 3rd line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	69.84	76.92	84.33	100.63	138.55	190.13	234.33	250.88	284.68	309.67	325.07
SQ stage IB and II	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	5.88	9.68	24.52	52.08	106.51	158.93	216.85	294.21	339.44	374.52	394.60
SQ stage III	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	316.08	330.51	361.38	427.57	486.76	567.82	662.41	767.85	818.49	808.79	793.68
SQ stage IV 1st line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	1,387.86	1,734.87	2,065.08	2,344.27	2,541.37	2,685.30	2,767.31	2,820.46	2,836.35	2,785.07	2,711.27
SQ stage IV 2nd line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030
	373.52	375.84	380.92	395.27	482.22	534.51	595.71	599.95	592.69	590.24	572.10
SQ stage IV 3rd line	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030

Forecast Data By Regimen

Sales (\$M)

Total Non-Small-Cell Lung Cancer	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030

Patient Share

Total Non-Small-Cell Lung Cancer	2020	2021
	-	-
Adeno stage IB and II	2020	2021
	-	-
Adeno stage III	2020	2021
	-	-
Adeno stage IV 1st line	2020	2021
	-	-
Adeno stage IV 2nd line	2020	2021
	-	-
Adeno stage IV 3rd line	2020	2021
	-	-
LC/O unverified histology stage IB and II	2020	2021
	-	-
LC/O unverified histology stage III	2020	2021
	-	-
LC/O unverified histology stage IV 1st line	2020	2021
	-	-
LC/O unverified histology stage IV 2nd line	2020	2021
	-	-
LC/O unverified histology stage IV 3rd line	2020	2021
	-	-
SQ stage IB and II	2020	2021
	-	-
SQ stage III	2020	2021
	-	-
SQ stage IV 1st line	2020	2021
	-	-
SQ stage IV 2nd line	2020	2021
	-	-
SQ stage IV 3rd line	2020	2021
	-	-

Patient Share

Total Non-Small-Cell Lung Cancer	2020	2021					
Japan	Europe	Major Markets	...	+	:	◀	

Contact Us

Introduction

Recent Forecast Changes

Methodology and Approach

Key Events and Assumptions

United States

France

Germany

Italy

Spain


United Kingdom

Country report includes drug forecasts by:

- Drug sales
- Patient share
- Treatment regimen (oncology)
- Treated population
- Compliance
- Price per treatment cycle

1. Use pivot buttons to expand views to include:
  - 1 - Sales by drug treatable sub populations
  - 2 - Drug classes
  - 3 - Specific brands/molecules
  - 4 - Generic and biosimilar erosion

# Market Forecast Dashboard



1. The Dashboard report is based on the data in the Market Forecast Assumptions report. The Dashboard has 2 informational tabs and 10 report tabs:

- Drug sales
- Regimen sales
- Drug patient share
- Regimen patient share
- Regimen cycles
- Regimen price per cycle
- Epidemiology
- Drug data table
- Regimen data table
- Epidemiology data table

2. Click on country/region, population, drug filters as indicated. Hold down CTRL button to select multiple filters. Do not select overlapping country/regions

# Alerts Request

Clarivate™ | DRG | Biopharma | Search within Biopharma | Browse All

Home / My Favorite Topics | View My Notifications

Diseases & Other Topics | Medtech

Start typing a disease or topic

**Autoimmune & Inflammation**

- ☐ Dermatology
  - ☐ Acne
  - ☐ Actinic Keratosis
  - ☐ Alopecia
  - ☐ Atopic Dermatitis/Atopic Eczema
  - ☐ Dermatitis/Eczema
  - ☐ Hidradenitis Suppurativa
  - ☐ Psoriasis
  - ☐ Urticaria

**Respiratory**

- ☐ Acute Respiratory Distress Syndrome
- ☐ Allergic Rhinitis
- ☐ Asthma
- ☐ Chronic Obstructive Pulmonary Disease
- ☐ Cystic Fibrosis
- ☐ Idiopathic Pulmonary Fibrosis
- ☐ Obstructive Sleep Apnea
- ☐ Sarcoidosis

**Rheumatology**

- ☐ Axial Spondyloarthritis
- ☐ Juvenile Idiopathic Arthritis
- ☐ Osteoarthritis
- ☐ Rheumatoid Arthritis
- ☐ Scleroderma (Systemic Sclerosis)
- ☐ Sjogren's Syndrome

**My Favorites**

**Email Preferences**

☐ Email me when there is updated content or new content published matching my favorites

Save Settings

1. To request email alerts of Disease Landscape & Forecast report key updates, select the bell icon

2. Select the disease markets that you are subscribed to, select the “Email Preferences” checkbox, then select the “Save Settings” button.

# Support Requests

Clarivate™ | DRG Medtech Search within Medtech

Home / Devices / **Peripheral Vascular Devices** Notifications Off

At a Glance **Market Insights** Commercial Targeting Brand Tracking Meet The Team

**Table of contents** Expand all

Search within Content

**GEOGRAPHIES**

- Global Market Trends
- United States**
  - Abstract
  - Executive Summary**
    - COVID-19 Updates
    - Market Highlights
    - Competitive Highlights
  - Key Report Updates
  - COVID-19 Analysis
  - Peripheral Vascular Device Market
  - Peripheral Vascular Stent Market
  - PTA Balloon Catheter Market
  - Atherectomy Device Market
  - Embolic Protection Device Market
  - Chronic Total Occlusion Crossing Device Market
  - Peripheral Vascular Accessory Device Market
  - Thrombectomy and Thrombolysis Device Market
  - Surgical Graft Market

**Executive Summary**

Last updated 30 December 2021

**COVID-19 Updates**

The market forecast and qualitative analysis in this report incorporate the impact of the COVID-19 pandemic. In addition to updates to standard report content, this report contains a COVID-19 Analysis chapter that centralizes key insights related to pandemic's impact on the market and competitive landscapes.

**Market Highlights**

**Factors Impacting the PV Device Market, by Product Type, US**

Factor	Impact on Market								
	PV Stents	PTA Balloon Catheters	Atherectomy Devices	EPDs	CTO Crossing Devices	PV Accessory Devices	Thrombectomy and Thrombolysis Devices	Surgical Grafts	Total Market
Positive Clinical Data	High	High	High	Medium	Low	Low	Medium	Low	High
Reimbursement	Low	High	High	Low	Low	Low	Medium	Low	High
Adoption of Premium-Priced Technology	High	High	Medium	Low	Medium	Medium	Medium	Low	Medium
Favorable Demographics	High	High	High	Low	Low	Low	Medium	Low	Medium

**Downloads**

**MAIN CONTENT**

- United States Full Report
- COVID-19 Methodology Attachment

**ADDITIONAL FILES**

- United States Table of Contents
- All Figures
- All Tables

**Meet the Team**

Xi Chen, PhD  
Manager

Ask the Expert View Bio

1

1. If you have additional questions or training/support requests, select “Ask the Expert” or “Contact Us” located under the “?” (Resources & updates) icon.



# Have a Question?

[DRG.support@clarivate.com](mailto:DRG.support@clarivate.com)  
[clarivate.com](https://clarivate.com)

## About Clarivate

Clarivate™ is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit [clarivate.com](https://clarivate.com).

---

© 2022 Clarivate. All rights reserved. Reproduction or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.